• In the first quarter of 2026, Ingredion reported lower results year on year, with net sales of US$1,792 million and net income of US$142 million, and cut its full-year 2026 earnings guidance while flagging plant disruptions and the planned closure of its Cabo, Brazil facility.
• Alongside weaker earnings, the company signaled a shift in its footprint and capital allocation by consolidating Latin American operations and continuing share buybacks, repurchasing 674,911 shares for US$78.42 million under its November 2025 authorization.
• We’ll now examine how the lowered 2026 earnings guidance and operational issues at the Argo facility affect Ingredion’s investment narrative.

Find 49 companies with promising cash flow potential yet trading below their fair value.

Ingredion Investment Narrative Recap

To own Ingredion, I think you have to believe its shift toward higher value ingredients and disciplined capital returns can offset pressure in legacy starch and sweetener products. The Q1 2026 earnings miss and Argo disruption bring that execution risk into focus, while updated guidance suggests the near term earnings reset is already on the table rather than a new, unexpected shock.

The most relevant recent announcement, in my view, is the reduced 2026 EPS guidance to US$9.60 to US$10.30 with operating income expected to be down high single digits. That update directly connects the Argo issues and Latin American softness to near term profit expectations, sharpening the trade off between operational challenges and ongoing shareholder returns like dividends and buybacks.

Yet behind the steady dividend and buybacks, the real risk investors should be aware of is Ingredion's growing dependence on...

Ingredion's narrative projects $7.8 billion revenue and $791.0 million earnings by 2029. This requires 2.4% yearly revenue growth and a $62.0 million earnings increase from $729.0 million today.

Uncover how Ingredion's forecasts yield a $126.57 fair value, a 19% upside to its current price.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community span roughly US$127 to US$198 per share, showing how far apart individual views can be. As you weigh those opinions against the recent guidance cut and operational issues at Argo, it is worth comparing several viewpoints before deciding how this earnings reset might shape Ingredion's longer term performance.

Explore 4 other fair value estimates on Ingredion - why the stock might be worth as much as 87% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Ingredion research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Ingredion research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ingredion's overall financial health at a glance.

No Opportunity In Ingredion?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.